Skip to Main Content
Table 2

eGFR decline according to quartiles of increasing baseline sTNFR1 stratified by diabetes at baseline

Participants (n)sTNFR1 (pg/mL)
Model 1
Model 2
Model 3
Median (25th, 75th percentile)Rangeβ95% CIP valueβ95% CIP valueβ95% CIP value
No diabetes (n = 259)             
 Q1 79 1,141 (1,039, 1,233) 465–1,285 Reference   Reference   Reference   
 Q2 72 1,433 (1,341, 1,529) 1,286–1,615 0.99 −0.80 to 2.78 0.28 0.98 −0.79 to 2.74 0.28 1.02 −0.74 to 2.78 0.26 
 Q3 62 1,770 (1,691, 1,960) 1,616–2,130 0.67 −1.22 to 2.55 0.49 0.50 −1.37 to 2.36 0.60 0.43 −1.44 to 2.28 0.65 
 Q4 46 2,386 (2,271, 2,922) 2,131–11,637 −0.60 −2.67 to 1.47 0.57 −1.67 −3.84 to 0.50 0.13 −1.23 −3.50 to 1.04 0.29 
sTNFR1* — — — −0.17 −2.06 to 1.71 0.86 −1.16 −3.19 to 0.87 0.26 −0.84 −2.90 to 1.21 0.42 
Diabetes (n = 194)             
 Q1 35 1,163 (1,002, 1,242) 773–1,282 Reference   Reference   Reference   
 Q2 41 1,468 (1,379, 1,523) 1,283–1,617 −0.27 −2.96 to 2.42 0.84 −0.34 −3.02 to 2.34 0.80 −0.46 −3.06 to 2.14 0.73 
 Q3 51 1,829 (1,760, 1,959) 1,618–2,094 −0.67 −3.24 to 1.89 0.60 −0.90 −3.48 to 1.67 0.49 −0.92 −3.41 to 1.57 0.47 
 Q4 67 2,965 (2,481, 3,920) 2,095–9,264 −4.64 −7.12 to−2.15 <0.001 −5.61 −8.44 to −2.78 <0.001 −4.22 −7.06 to −1.38 0.004 
sTNFR1* — — — −4.34 −6.19 to−2.49 <0.001 −6.78 −9.34 to −4.21 <0.001 −5.18 −7.82 to −2.54 <0.001 
Participants (n)sTNFR1 (pg/mL)
Model 1
Model 2
Model 3
Median (25th, 75th percentile)Rangeβ95% CIP valueβ95% CIP valueβ95% CIP value
No diabetes (n = 259)             
 Q1 79 1,141 (1,039, 1,233) 465–1,285 Reference   Reference   Reference   
 Q2 72 1,433 (1,341, 1,529) 1,286–1,615 0.99 −0.80 to 2.78 0.28 0.98 −0.79 to 2.74 0.28 1.02 −0.74 to 2.78 0.26 
 Q3 62 1,770 (1,691, 1,960) 1,616–2,130 0.67 −1.22 to 2.55 0.49 0.50 −1.37 to 2.36 0.60 0.43 −1.44 to 2.28 0.65 
 Q4 46 2,386 (2,271, 2,922) 2,131–11,637 −0.60 −2.67 to 1.47 0.57 −1.67 −3.84 to 0.50 0.13 −1.23 −3.50 to 1.04 0.29 
sTNFR1* — — — −0.17 −2.06 to 1.71 0.86 −1.16 −3.19 to 0.87 0.26 −0.84 −2.90 to 1.21 0.42 
Diabetes (n = 194)             
 Q1 35 1,163 (1,002, 1,242) 773–1,282 Reference   Reference   Reference   
 Q2 41 1,468 (1,379, 1,523) 1,283–1,617 −0.27 −2.96 to 2.42 0.84 −0.34 −3.02 to 2.34 0.80 −0.46 −3.06 to 2.14 0.73 
 Q3 51 1,829 (1,760, 1,959) 1,618–2,094 −0.67 −3.24 to 1.89 0.60 −0.90 −3.48 to 1.67 0.49 −0.92 −3.41 to 1.57 0.47 
 Q4 67 2,965 (2,481, 3,920) 2,095–9,264 −4.64 −7.12 to−2.15 <0.001 −5.61 −8.44 to −2.78 <0.001 −4.22 −7.06 to −1.38 0.004 
sTNFR1* — — — −4.34 −6.19 to−2.49 <0.001 −6.78 −9.34 to −4.21 <0.001 −5.18 −7.82 to −2.54 <0.001 

Data are milliliters per minute per 1.73 m2 per year unless otherwise indicated. Model 1 was adjusted for baseline age and sex. Model 2 was adjusted for baseline age, sex, and CKD-EPI eGFR. Model 3 was adjusted for baseline age, sex, CKD-EPI eGFR, and uACR. CKD-EPI eGFR was calculated using the CKD-EPI eGFR equation based on serum creatinine without the correction for African American ethnicity.

*sTNFR1 was transformed using the natural logarithm.

Close Modal

or Create an Account

Close Modal
Close Modal